Hypercalcitoninemia in chronic kidney disease: an old issue, a new perspective?

Eur Thyroid JPublished 8 Jun 2026Retrospective cross-sectional study

Cite

Authors' conclusion

Ct levels may be mildly elevated in advanced CKD; until stage 3, the increase is negligible.

Study context

Population: Group 1: anonymous subjects with calcitonin (Ct) and creatinine measurements; Group 2: patients with chronic kidney disease (CKD)Group 1: 9,450 subjects
Participants: 4,294 / 4,022 / 135

Exposure: CKD vs controls
Control seriesn = 4,294reference
CKD seriesn = 4,022
Group 2n = 135
Outcome: Ct levels in CKD patients (chemiluminescent immunoassay)

Methodological detailstwo population datasets

As reported in the abstract

Median Ct

CKD series1.0median · IQR 1.0–2.8 · ng/L

Control series1.0median · IQR 1.0–2.9 · ng/L

Group 23.7median · IQR 1.0–7.0 · ng/L

Median Ct by CKD stage: stage 2 1.00 (IQR 1.00-2.40), stage 3 1.20 (IQR 1.00-4.30), stage 4 2.80 (IQR 1.00-6.75), stage 5 4.55 (IQR 1.00-11.30) ng/L: P < 0.001

Observational data: associations, not effects.

Outcome	Values	P value
Median Ct by CKD stage (Group 1)Between Stage 2 and Stage 5 · median Ct differed significantly by CKD stage (stages 2–5)	Stage 2 median 1.00 (IQR 1.00–2.40) ng/L · Stage 3 median 1.20 (IQR 1.00–4.30) ng/L · Stage 4 median 2.80 (IQR 1.00–6.75) ng/L · Stage 5 median 4.55 (IQR 1.00–11.30) ng/L	P < 0.001
Ct >10 ng/L by CKD stage vs controls (Group 1)	Stage 4 16.7% · Stage 5 31.1%

Ct >10 ng/L by CKD stage vs controls (Group 1) — Ct >10 ng/L in controls: 4.3%
Ct >10 ng/L by CKD stage vs controls (Group 1) — Ct >10 ng/L significantly associated with CKD stage (stage 4 and stage 5 vs controls): P < 0.001

Correlation of Ct with creatinine (Group 1)

Ct in Group 2 (135 CKD patients)

Hypercalcitoninemia in chronic kidney disease: an old issue, a new perspective? Eur Thyroid J. Published 8 June 2026. doi:10.1530/etj-26-0021

Composed by AI from the published abstract and checked against it. How Briefs are made →